Development of vaccines for Plasmodium vivax malaria
- Author(s)
- Mueller, I; Shakri, AR; Chitnis, CE;
- Details
- Publication Year 2015-12-22,Volume 33,Issue #52,Page 7489-95
- Journal Title
- Vaccine
- Publication Type
- Journal Article
- Abstract
- Plasmodium vivax continues to cause significant morbidity outside Africa with more than 50% of malaria cases in many parts of South and South-east Asia, Pacific islands, Central and South America being attributed to P. vivax infections. The unique biology of P. vivax, including its ability to form latent hypnozoites that emerge months to years later to cause blood stage infections, early appearance of gametocytes before clinical symptoms are apparent and a shorter development cycle in the vector makes elimination of P. vivax using standard control tools difficult. The availability of an effective vaccine that provides protection and prevents transmission would be a valuable tool in efforts to eliminate P. vivax. Here, we review the latest developments related to P. vivax malaria vaccines and discuss the challenges as well as directions toward the goal of developing highly efficacious vaccines against P. vivax malaria.
- Publisher
- Elseveir
- Research Division(s)
- Population Health And Immunity
- PubMed ID
- 26428453
- Publisher's Version
- https://doi.org/10.1016/j.vaccine.2015.09.060
- Open Access at Publisher's Site
http://www.sciencedirect.com/science/article/pii/S0264410X15013365- NHMRC Grants
- NHMRC/1021544, NHMRC/1043345,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2016-02-29 12:20:48
Last Modified: 2019-04-01 08:57:43